Skip to main content
Search

# Drug Repurposing

2 related articles

Subscribe to updates
  1. CircRNA binding-site prediction stops reading only the RNA: CPRISP encodes the protein too, reaching mean AUC 0.9874 across 37 benchmarks

    Prediction of circRNA-RBP binding sites has leaned on transcript features while making limited use of protein-specific information. CPRISP feeds circRNA sequence composition, physicochemical properties, secondary structure and pretrained embeddings together with global and local protein-sequence representations into a multi-scale residual classifier. Across 37 benchmark datasets it reaches a mean AUC of 0.9874 versus 0.9230 for CircSSNN, and holds 0.9861 under sequence-similarity-controlled partitions.

  2. bioRxiv

    HANAMI predicts drug-gene-disease motifs with heterogeneous graph contrastive learning, improving up to about 6% over state-of-the-art baselines and holding an ~18% edge in zero-shot settings

    The authors present HANAMI (Heterogeneous grAph coNtrastive leArning for drug-gene-disease Motif predIction), a multi-view deep graph learning framework that integrates heterogeneous biomedical knowledge such as chemical structures, genomic sequences, and clinical phenotypes and uses relation-aware topology encoding, structure-aware aggregation, and contrastive learning to predict drug-gene-disease motifs; systematic evaluation on benchmark datasets shows up to about 6% improvement over existing state-of-the-art methods in motif prediction, an approximately 18% performance advantage maintained in zero-shot settings involving previously unseen entities, and the ability to prioritize drug-disease relationships investigated in Phase II or III trials while identifying candidate genes suggestin

You’re all caught up